PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12728257-5	2003	In the study described here, Bcr-Abl-positive cells treated with tyrosine-kinase inhibitors such as herbimycin A, genistein or STI571 lost their phosphotyrosine-containing proteins, but were still extremely resistant to apoptosis.	herbimycin	100-112	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	29-36	
1564963-0	1992	Induction of differentiation of human leukemia cells with a structurally altered c-abl (bcr/abl) gene by herbimycin A, an inhibitor of tyrosine kinase activity.	herbimycin	105-117	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	81-86	
1564963-0	1992	Induction of differentiation of human leukemia cells with a structurally altered c-abl (bcr/abl) gene by herbimycin A, an inhibitor of tyrosine kinase activity.	herbimycin	105-117	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	88-95	
2910452-4	1989	In order to understand the relationship between induction of differentiation and reduction of tyrosine phosphorylation by the c-abl gene product, the effect that herbimycin A, a selective inhibitor of intracellular tyrosine kinase activity, exerts on the differentiation of K562 cells was examined.	herbimycin	162-174	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	126-131	
1651810-5	1991	The inhibition of v-abl tyrosine kinase activity preceded induction of differentiation of the cells treated with tyrosine kinase inhibitors such as genistein, herbimycin A, and erbstatin.	herbimycin	159-171	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	18-23	
14529384-2	2003	In the mid 1980s, it was found that the benzoquinone ansamycin antibiotics (herbimycin A, geldanamycin, and macbecin) reversed v-Src transformed cells to normal phenotypes, and Bcr-abl was subsequently suggested to be the molecular target for the treatment of chronic myelogenous leukemia through a study using herbimycin A for its selective antioncogenic activity.	herbimycin	76-88	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	177-184	
14529384-2	2003	In the mid 1980s, it was found that the benzoquinone ansamycin antibiotics (herbimycin A, geldanamycin, and macbecin) reversed v-Src transformed cells to normal phenotypes, and Bcr-abl was subsequently suggested to be the molecular target for the treatment of chronic myelogenous leukemia through a study using herbimycin A for its selective antioncogenic activity.	herbimycin	311-323	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	177-184	
11409908-4	2001	Several compounds have now been identified as relatively selective inhibitors of BCR-ABL, including members of the tyrphostin family, herbimycin A and most importantly the 2-phenylaminopyrimidine ST1571.	herbimycin	134-146	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	81-88	
11960322-1	2002	Geldanamycin (GA), herbimycin A and radicicol bind heat-shock protein-90 (Hsp90) and destabilize its client proteins including v-Src, Bcr-Abl, Raf-1, ErbB2, some growth factor receptors and steroid receptors.	herbimycin	19-31	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	134-141	
8139288-6	1994	The sensitivities of the Ph1-positive cell lines to herbimycin A derivatives were different from the data on the rat kidney cell line infected with Rous sarcoma virus (v-src) derived from a previous study, suggesting bcr/abl kinase may differ in sensitivity from other tyrosine kinases.	herbimycin	52-64	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	217-224